Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Aires Pharmaceuticals signs technology license agreement with NIH
The technology, identified at the National Institutes of Health’s (NIH) National Heart, Blood and Lung Institute, shows that nitrite, which is converted by the body into nitric oxide,
The technology, identified at the National Institutes of Health’s (NIH) National Heart, Blood and Lung Institute, shows that nitrite, which is converted by the body into nitric oxide,
Under the terms of the collaboration, Bayer HealthCare receives exclusive worldwide rights to develop anticancer compounds to the target using ImmunoGen’s maytansinoid cell-killing agents and linker technology. Bayer
Under the terms of this agreement, NxStage will supply the Streamline airless blood tubing set as well as MasterGuard and other products to Renal Advantage’s dialysis center network.
Early Lyme disease research has resulted in three significant findings. First, the study team has identified and synthesized ‘key’ peptides that are predicted to have high binding affinity
The novel dressing features a polymer-based core that could help change the way clinicians manage heavily exuding wounds, currently a significant issue in wound care. Ed Quilty, CEO
Mr Johnson has agreed to serve as a consultant to the company until March 31, 2009, the end of the company’s current fiscal year, to assist with transition
Oncure Medical said that the move helped the company improve its ability to recruit and retain talent and meet its spatial needs as a result of Denver’s lower
The agreement puts in place a number of activities to help progress Metabolon’s Prostarix line of prostate cancer diagnostics including an exclusive license for Metabolon to use prostate
The program was previously the subject of a partnership with GlaxoSmithKline’s cardiovascular centre of excellence for drug discovery unit. Vitae’s other research programs include a substantial collaboration with
Under the agreement, Laureate will produce Tolerx’s humanized anti-GITR antibody known as TRX518, which is currently in development for cancer and chronic viral indications. Robert Broeze, president and